(2R,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid结构式
|
常用名 | (2R,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | 英文名 | (2R,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
|---|---|---|---|---|
| CAS号 | 159573-88-3 | 分子量 | 216.26 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C8H12N2O3S | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A |
| 英文名 | (2R,5R,6R)-6-amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
|---|
| 分子式 | C8H12N2O3S |
|---|---|
| 分子量 | 216.26 |
| InChIKey | NGHVIOIJCVXTGV-ZMIZWQJLSA-N |
| SMILES | CC1([C@H](N2[C@H](S1)[C@@H](C2=O)N)C(=O)O)C |
|
实验名称:insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen
来源:846
靶标:N/A
External Id:5mMGluc_INS1E_InsulinRelease_40mMGluc_SP
|
|
实验名称:GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen
来源:846
靶标:N/A
External Id:GSK3b_inh_pretreated_Viability_ATP_HCT116_SP
|
|
实验名称:Cytotoxicity counterscreen for inhibitors of SARS-CoV-2 cell entry
来源:NCGC
靶标:N/A
External Id:TRND-SARS-CoV-2-cytotox-48hr
|
|
实验名称:GLP1 secretion from NCI-H716 cells-screen
来源:846
靶标:N/A
External Id:hNCI-H716_GLP1_Secretion_SP
|
|
实验名称:VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen
来源:846
靶标:N/A
External Id:VEGF_ADSC_ECFC_Angio_CD31_TubeArea_SP
|
|
实验名称:SW480 viability from Cell TiterGlo-screen
来源:846
靶标:N/A
External Id:Basal_Viability_ATP_SW480_SP
|
|
实验名称:Primary qHTS to identify inhibitors of SARS-CoV-2 cell entry
来源:NCGC
External Id:TRND-SARS-CoV-2-PP
|
|
实验名称:HCT116 viability from Cell TiterGlo-screen
来源:846
靶标:N/A
External Id:Basal_Viability_ATP_HCT116_SP
|
|
实验名称:DLD-1 viability from Cell TiterGlo-screen
来源:846
靶标:N/A
External Id:Basal_Viability_ATP_DLD-1_SP
|
|
实验名称:Primary qHTS for inhibitors of NSP2Pro chikungunya virus (CHIKV)
来源:NCGC
External Id:APP-Toga-CHIKV-nsp2-p
|